15 October 2024:

TROG Cancer Research has made a commitment to embracing the principles of diversity, equity and inclusion (DEI) across all aspects of our work, with the launch of a new DEI policy.

The Diversity, Equity and Inclusion (DEI) Policy provides guidelines to ensure DEI principles are embedded across all organisational and clinical research activities, respecting and valuing the unique experiences and perspectives of all individuals.

The policy covers all aspects of TROG’s operations, including staff, volunteers, members, research participants, partners and clinical research activities.

The policy includes, but is not limited to, commitments to:

• Ensuring clinical research teams and participant pools reflect population diversity, aiming to understand and address the unique cancer challenges across different demographics.
• Providing equitable access to clinical trials and research opportunities, removing systemic barriers to participation and providing support for underrepresented groups.
• Fostering a culture where diverse perspectives, backgrounds, and ideas are welcomed and actively sought in our decision-making processes.

TROG President A/Prof Puma Sundaresan said ensuring equity, diversity and inclusion across all elements of clinical trial design and implementation are key to achieving equitable cancer outcomes.

“This policy underpins TROG’s commitment to driving equity, diversity and inclusion in all that we do, from the way we recruit patients for clinical trials, to the TROG workforce and collaborations with partner organisations.”

TROG Cancer Research CEO Susan Goode said the policy was developed in recognition of the fact that excellence in cancer research and patient care is fundamentally connected to diversity, equity and inclusion.

“This commitment aligns with our mission to revolutionise cancer care through impactful radiation medicine research to cure cancer and improve quality of life,” she added.

Read the Diversity, Equity and Inclusion (DEI) Policy.